DBV Tech grabs $25M C round for allergy drug trials

A pair of new investors--InnoBioFund and Lundbeckfond Ventures--has taken the lead on a $25.5 million Series C round for France's DBV Technologies, And the biotech plans to use that money to fuel its work on new therapies for severe food allergies.

According to Genetic Engineering & Biotechnology News the French company gained FDA clearance on clinical trial work for its peanut allergy therapy with Phase Ib studies now underway. The NIH is supporting Phase II work, which is scheduled to get started at the middle of this year. Shire and Alto Invest joined the round with existing investors Sofinnova Partners and Alk Abello.

- here's the story from Genetic Engineering & Biotechnology News

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.